MTOR and prostate cancer: As a strategy to induce the maximal inhibition of this pathway in cancer cells, allosteric mTOR rapalogs were combined with a proof of principle dual PI3K/mTOR kinase inhibitor (PI-103) and shown to exhibit more activity than single agents in human ovarian and prostate cancer cells with alterations in the pathway [81].